Pharsight

Isentress patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(8 days from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(11 months ago)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(11 months ago)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(5 months ago)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(5 months ago)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(6 months from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(5 years from now)

US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Oct, 2030

(7 years from now)

US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(7 years from now)

US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(8 years from now)

Isentress is owned by Merck Sharp Dohme.

Isentress contains Raltegravir Potassium.

Isentress has a total of 11 drug patents out of which 4 drug patents have expired.

Expired drug patents of Isentress are:

  • US7217713
  • US7435734
  • US7435734*PED
  • US7217713*PED

Isentress was authorised for market use on 12 October, 2007.

Isentress is available in tablet;oral dosage forms.

Isentress can be used as treatment of hiv-1 infection, treatment of hiv infection, treatment of hiv infection; integrase inhibition for the treatment of hiv infection.

The generics of Isentress are possible to be released after 30 March, 2032.

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents
ISENTRESS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8852632 MSD SUB MERCK Pharmaceutical formulation containing a release rate controlling composition
Jan, 2028

(4 years from now)

US8771733 MSD SUB MERCK Pharmaceutical composition containing an anti-nucleating agent
Jun, 2030

(6 years from now)

Isentress is owned by Msd Sub Merck.

Isentress contains Raltegravir Potassium.

Isentress has a total of 2 drug patents out of which 0 drug patents have expired.

Isentress was authorised for market use on 12 October, 2007.

Isentress is available in tablet;oral dosage forms.

Isentress can be used as treatment of hiv infection.

The generics of Isentress are possible to be released after 02 June, 2030.

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage

ISENTRESS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic